Naransi®

1 tablet contains 2.5 mg naratriptan, №4

PHARMACOLOGIC PROPERTIES
ATC code: N02CC02, Selective 5-HT1 receptor agonists
Naratriptan has been shown to be a selective agonist for 5 hydroxytryptamine1 (5-HT1) receptors mediating vascular contraction. This receptor is found predominantly in intracranial (cerebral and dural) blood vessels. Naratriptan has high affinity for human cloned 5-HT1B and 5-HT1D receptors; the human 5-HT1B receptor is thought to correspond to the vascular 5-HT1 receptor mediating contraction of intracranial blood vessels. Naratriptan has little or no effect at other 5-HT receptor (5-HT2, 5-HT3, 5-HT4 and 5-HT7) subtypes.
The causes of migraine are not clearly understood; however, the efficacy of naratriptan is believed to be due to their activity as 5HT (serotonin) agonists.

THERAPEUTIC INDICATIONS
NARANSI tablets are indicated for the acute treatment of migraine attacks with or without aura.